MedPath

A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer

Phase 1
Completed
Conditions
Small Cell Lung Carcinoma
Interventions
Registration Number
NCT02874664
Lead Sponsor
Stemcentrx
Brief Summary

Study to evaluate the effect of rovalpituzumab tesirine on cardiac ventricular repolarization in subjects with small cell lung cancer (SCLC).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
46
Inclusion Criteria
  • Histologically or cytologically confirmed extensive-stage small-cell lung cancer (SCLC).
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
  • Adequate hematologic and organ function as confirmed by laboratory values
Exclusion Criteria
  • Clinically significant cardiac abnormalities including QRS duration of >120 msec; QTcF >470 msec for women and >450 msec for men; Abnormal cardiac rhythm; Clinically significant cardiac valve abnormality; Documented history of left ventricular ejection fraction <0.30 within 6 months; Permanent pacemaker or automatic implantable cardioverter defibrillator; History of torsades de pointes, congenital long QT syndrome, or family history of long QT syndrome or sudden death
  • Recent or ongoing serious infection
  • Women who are pregnant or breastfeeding
  • Prior exposure to a pyrrolobenzodiazepine (PBD)-based drug, prior participation in a rovalpituzumab tesirine clinical trial, or known hypersensitivity to rovalpituzumab tesirine or excipient contained in the drug formulation.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Rovalpituzumab TesirineRovalpituzumab Tesirine0.3 mg/kg rovalpituzumab tesirine intravenously on Day 1 of every 6-week treatment cycle for 2 cycles omitting every third cycle
Primary Outcome Measures
NameTimeMethod
Change in QTcF interval from baseline QTcF following treatment with rovalpituzumab teserine as measured by extracting quantitative ECG parameters from ambulatory Holter monitors.12 weeks
Secondary Outcome Measures
NameTimeMethod
Relationship between plasma rovalpituzumab tesirine concentration and change in QTcF interval from baseline.12 weeks
Incidence of proarrhythmic adverse events stratified by change in QTcF from baseline of less than 10 ms or greater than 10 ms.12 weeks
Progression free survivalBaseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 24 months.
Area Under the Curve (AUC)Cycles 1 and 2: Day 1 (predose, 30 min, 2 and 4 hours postdose) and days 2,3,4,8,15,and 29; Cycles 4,5,7,8: Day 1 predose and 30 min postdose.
Change in QRS duration interval from baseline QRS duration following treatment with rovalpituzumab teserine as measured by extracting quantitative ECG parameters from ambulatory Holter monitors.12 weeks
Incidence of adverse events.From first dose through 30 days post-last-dose
Clinical benefit ratioBaseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 24 months.
Change in RR interval from baseline RR following treatment with rovalpituzumab teserine as measured by extracting quantitative ECG parameters from ambulatory Holter monitors.12 weeks
Change in PR interval from baseline PR following treatment with rovalpituzumab teserine as measured by extracting quantitative ECG parameters from ambulatory Holter monitors.12 weeks
Duration of responseBaseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 24 months.
Change in waveform composition interval from baseline waveform composition following treatment with rovalpituzumab teserine as measured by extracting quantitative ECG parameters from ambulatory Holter monitors.12 weeks
Objective response rateBaseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 24 months.
Maximum Plasma Concentration (Cmax)Cycles 1 and 2: Day 1 (predose, 30 min, 2 and 4 hours postdose) and days 2,3,4,8,15,and 29; Cycles 4,5,7,8: Day 1 predose and 30 min postdose.
Overall survivalBaseline, every 6 weeks until 6 months, then every 12 weeks until disease progression, assessed up to 24 months.

Trial Locations

Locations (15)

University of California Los Angeles

🇺🇸

Los Angeles, California, United States

Winship Cancer Institute, Emory University

🇺🇸

Atlanta, Georgia, United States

University of Chicago Medical Center

🇺🇸

Chicago, Illinois, United States

Parkview Research Center

🇺🇸

Fort Wayne, Indiana, United States

Baptist Health Lexington

🇺🇸

Lexington, Kentucky, United States

Karmanos Cancer Institute

🇺🇸

Detroit, Michigan, United States

Henry Ford Hospital

🇺🇸

Detroit, Michigan, United States

Roswell Park Cancer Institute

🇺🇸

Buffalo, New York, United States

University of Cincinnati

🇺🇸

Cincinnati, Ohio, United States

University Hospitals Case Medical Center

🇺🇸

Cleveland, Ohio, United States

Scroll for more (5 remaining)
University of California Los Angeles
🇺🇸Los Angeles, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.